Forsyth Barr broker Lyn Howe said yesterday new products were expected to be a feature of discussions at the investor day.
Last investor day, in Sydney last year, FPH released two new products on the day, so there was potential for another product launch.
FPH had an attractive growth outlook in both its respiratory and acute care (RAC) and obstructive sleep apnoea (OSA) products, which was topical in the light of patent disputes and new products, she said.
''Product innovation is a critical part of its business model with the array of new products released, and in the pipeline, supportive to our expectations for above-industry growth in the medium-term.''
The investor day would provide access to FPH senior management based in Mexico, the US and New Zealand.
The key themes on which Forsyth Barr was seeking more insight were Mexico capacity expansion, new products, and new applications, Ms Howe said.
The company recently announced it would start expansion of its manufacturing facilities in both Auckland and Mexico to support future growth for the company.
Manufacturing in Mexico had been a key driver of gross margin expansion for FPH over the last five years and further capacity should support additional margin growth.
It was hoped FPH would provide some insight into the location and site for the new Mexican facility, provide details of capacity at the current facility and talk about where Mexican production could get to and over what timeframe, she said.
FPH expected to spend about $200million during the next four to five years across Auckland and Mexico, expanding its manufacturing capacity. It would include a new building on its Auckland site and a greenfield and land purchase in Mexico.
FPH began manufacturing in lower-cost Mexico in March 2010 and now manufactured about 33% of its total consumables there. Cost of production was materially lower in Mexico and also provided risk mitigation, Ms Howe said.
New applications, or applications outside of invasive ventilation, were a key topic of discussion at the last investor day and were likely to again be a key feature of discussion of the US-Mexico investor day.
The strong growth outside of the company's traditional invasive ventilation market over recent results was encouraging for future earnings growth, particularly in light of the current low penetration versus the market opportunity, she said.
Consumables for new applications continued to become an increasingly important part of FPH's business, making up 51% of RAC consumables revenue in the 2016 financial year.
New applications included non-invasive ventilation, high-flow oxygen therapy and surgical.
Growth had been more than 20% for at least the last five years, Ms Howe said.
''The market opportunities are sizeable, particularly in oxygen therapy, and it is still early days. We have confidence strong growth can continue in new applications in the medium-term, given the material market opportunity and current low penetration levels.''
FPH had 138 US patents and 329 US patent applications at the end of the 2016 financial year. That compared to 559 non-US patents and 582 non-US patent applications.
Patents had a life of about 20 years. The average life of FPH's patent portfolio was 15.8 years, indicating a ''fairly new'' portfolio, she said.
The US was one market where the company was in a patent dispute with ResMed.
''We can only conclude the patent dispute between FPH and ResMed will be a time-consuming, distracting and costly exercise for both parties.''
It was a longstanding issue and no resolution had been reached to date, she said.
